重庆医学2011，Vol.40Issue(20)：1997-1999,2002,4.DOI:10.3969/j.issn.1671-8348.2011.20.008
厄洛替尼挽救治疗吉非替尼治疗失败的晚期非小细胞肺癌疗效观察
Evaluation of erlotinib as a salvage treatment for non-small-cell lung cancer(NSCLC)patients after gefitinib failure
罗大先 1龙建林 1丘金凤 1余敏 1邹炳文 1周麟 1卢铀 1黄媚娟1
作者信息
- 1. 四川大学华西医院肿瘤中心胸部肿瘤科,成都,610041
- 折叠
摘要
Abstract
Objective To evaluate the response rate and adverse effects of erlotinib as a salvage treatment for non-small-cell lung cancer(NSCLC)patients after gefitinib treatment.Methods Patients with advanced/metastasis NSCLC received Erlotinib until disease progression or intolerable toxicity as a salvage treatment after failure of gefitinib from December 2005 to November 2009,Response Rate( RR) , Disease Control Rate ( DCR) , Progression-Free Survival ( PFS), Overall-Survival ( OS) and side-effects were observed.Results Till June 2009,22 patients were enrolled and all were evaluated for response and toxicity.With a median follow-up of 5.5 months , two cases obtained Partial Response( PR) ,12 cases Stable Disease( SD) and eight cases Progression Disease( PD) , resulting in a RR of 9.1％ and DCR of 63.6％.Median PFS and OS were 3 months and 5.5 months,respectively.Epidermal Growth Factor Receptor( EGFR)mutational analysis was performed in four evaluable caeses,two of them were without EGFR mutation.All the four patients achieved disease control after erlotinib treatment.A male patient who was a smoker with adenocarcinoma had brain metastases and received CR after Erlotinib treatment.Patients who had SD by prior gefitinib treatment obtained significantly higher DCR(90％ vs58.37％,P=0.031).RR, PFS and OS were 20％ ,3 months and 5.5months in those patients , respectively.Grade 3 to 4Toxic effects including pulmonary interstitial fibrosis ( 1/22 ) , rash ( 1/22 ) and liver dysfunction ( 1/22 ) were observed.Conclusiorrt Erlotinib as a salvage treatment might be effective for NSCLC patients after failure of gefitinib treatment.Those who had gained SD from prior gefitinib treatment achieved higher disease control rate.关键词
癌/非小细胞肺/厄洛替尼/吉非替尼Key words
corcinoma/ non-small cell lung / erlotinib / gefitinib引用本文复制引用
罗大先,龙建林,丘金凤,余敏,邹炳文,周麟,卢铀,黄媚娟..厄洛替尼挽救治疗吉非替尼治疗失败的晚期非小细胞肺癌疗效观察[J].重庆医学,2011,40(20):1997-1999,2002,4.
